Lucid posted deeper Q2 losses and cut its 2025 outlook, but strong liquidity and a key Uber deal support long-term growth.

Discover Vistagen's Q1 2026 progress! From Phase III trials of fasedienol to robust financial backing, explore its potential as a breakthrough in ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...